Funding for this research was provided by:
Stiftelsen Konung Gustaf V:s 80-årsfond (FAI-2016-0273)
Innovative Medicines Initiative (115142, 777357)
Received: 12 September 2019
Accepted: 22 April 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: The study has been performed in compliance with the Declaration of Helsinki, with informed consent obtained from all study participants, and ethical approval granted at the Regional Ethical Review Board in Stockholm.
: Not applicable.
: The authors declare that they have no conflicting financial interest and have not received funding from commercial sources in the context of this study.Karolinska Institutet has been a partner with Thermo Fisher Scientific within the Innovative Medicines Initiative BTCure, a public–private partnership between the EU and the European Federation of Pharmaceutical Industries (ExternalRef removed). Thermo Fisher Scientific has contributed to this consortium with in-kind contributions for the development of the microarray multiplex assay used in the current study. LMA is employed by Thermo Fischer Scientific. JR is a member of the Thermo Fisher Scientific advisory board.RH is a co-inventor of the patent US Patent 7 148 020, protecting the use of the CitC1 and C1 peptides. KS is co-inventor of patents US 13/141,960 and EP 09799354.7, describing the diagnostic use of the hnRNP-A3 peptide epitopes. GS is co-inventor of several international patents about ACPA antigens held by BioMérieux Cy and licenced to Eurodiagnostica Cy and Axis-Shield Cy, for commercialization of the CCP2 assays; according to French laws, part of the royalties is paid to the Toulouse III University and the University Hospital of Toulouse. KL is co-inventor of the patent US12/524,465, describing the diagnostic use of the CEP-1 epitope.